Morgan Stanley flags emerging opportunity in this sector

Investing.com -- Morgan Stanley analysts said in a report on Tuesday that “the stars are aligning” for SMID Cap biotech, arguing that three underappreciated forces could unlock a period of outperformance and dealmaking across the sector.

The firm cites “~$325bn in net cash on commercial stage SMID Cap & Large Cap Biopharma balance sheets,” what it calls investors’ “overreaction to DOGE-driven cuts at the FDA,” and a looming “$176bn patent cliff” for large-cap peers.

In its industry outlook, led by analyst Sean Laaman, Morgan Stanley remarked: “We see a growth spurt ahead for commercial-stage SMID Cap Biotech names with a ~14% revenue CAGR and revenue growing from ~$57bn in 2025 to ~$109bn by 2030E.”

The bank added that total SMID Cap net cash is set to rise to “~$150bn by 2030E,” while large-cap biopharma could reach “~$210bn in 2030.”

Analysts argue that concerns over the regulatory backdrop have been exaggerated. “Fears of regulatory uncertainty…after DOGE are overdone,” Morgan Stanley wrote, noting that companies are “mostly hitting FDA target dates.”

The firm added that the agency “doesn’t want to be seen as a hurdle for U.S. innovation given the rise of China Biotech competition.”

Furthermore, the bank sees the patent cliff as a major catalyst for strategic activity. For large-cap biopharma, Morgan Stanley estimates that “~$176bn of revenue (~35% of aggregate 2025 revenue) will lose exclusivity by 2030,” requiring companies to “execute on existing pipeline and potentially build it via M&A.”

The firm says client conversations suggest investors “don’t fully grasp how attractive SMID Cap Biotech companies with commercial-stage products may become,” highlighting the potential for both “re-rating and M&A activity.”

With improving fundamentals and rising cash balances, Morgan Stanley expects biotech deal flow to accelerate.

You May Also Be Interested In